Loading
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Previous close
$9.56
+$0.10 · +1.06%
Regular session · ET · Market data may be delayed.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Day range
Current $9.56
52-week range
Current $9.56
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Sell
Trim exposure — unfavorable risk-reward
Valuation
2
Overpriced
Sentiment
43
Mixed
Risk
55
Elevated Risk
Momentum
37
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Day range
Current $9.56
52-week range
Current $9.56
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (EUR) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 48.27M EUR | 155.84M EUR | 54M EUR | 172.83M EUR | 34.76M EUR |
| Gross profit | 48.27M EUR | 155.84M EUR | 54M EUR | 172.83M EUR | 34.76M EUR |
| Research and development | 183.83M EUR | 148.08M EUR | 118.66M EUR | 106.78M EUR | 87.57M EUR |
| Selling, general, and administrative | 51.18M EUR | 46.45M EUR | 38.2M EUR | 36.12M EUR | 33.81M EUR |
| Operating expenses | 230.28M EUR | 194.45M EUR | 155.72M EUR | 142.88M EUR | 121.06M EUR |
| Interest income | 17.18M EUR | 25M EUR | 13.85M EUR | 2.48M EUR | 133K EUR |
| Interest expense | 946K EUR | 886K EUR | 831K EUR | 1.04M EUR | 566K EUR |
| Depreciation and amortization | 12.4M EUR | 12.23M EUR | 7.23M EUR | 6.97M EUR | 5.26M EUR |
| Operating income | −182.02M EUR | −38.62M EUR | −101.73M EUR | 29.95M EUR | −86.29M EUR |
| Net income | −196.45M EUR | 15.22M EUR | −94.65M EUR | 27.7M EUR | −93.34M EUR |
Company facts updated Sep 6, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$17.00
77.82% upsideFunds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR Portfolio Developed World ex-US ETFSPDW1.85M0.00%42.37B USD0.03%$52.31+0.40%
ALPS Medical Breakthroughs ETFSBIO1.77M0.71%243.98M USD0.50%$67.66+0.52%
Tema Oncology ETFCANC1.73M0.80%216.51M USD0.99%$44.0502-0.70%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP1.7M0.06%2.67B USD0.20%$67.695+0.29%
Fidelity Nasdaq Composite Index ETFONEQ575.14K0.01%10.35B USD0.21%$104.46-0.29%
State Street SPDR S&P International Small Cap ETFGWX448.19K0.05%939.97M USD0.40%$47.03+0.69%
Virtus Biotech Clinical Trials ETFBBC316.33K0.62%50.31M USD0.65%$53.71+0.60%
Innovator U.S. Small Cap Managed Floor ETFRFLR53.88K0.06%96.02M USD0.89%$32.785+0.33%State Street SPDR Portfolio Developed World ex-US ETFSPDWALPS Medical Breakthroughs ETFSBIOTema Oncology ETFCANCState Street SPDR S&P Kensho New Economies Composite ETFKOMPFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P International Small Cap ETFGWXVirtus Biotech Clinical Trials ETFBBCInnovator U.S. Small Cap Managed Floor ETFRFLRAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
